Research projects directed towards looking for solutions to the cancer menace have been around for many years. Experts like Clay Siegall have been working together to deliver solutions that are reliable and capable of offering a permanent cure. One of the research institutes that have pursued this course diligently is Seattle Genetics, which was founded in 1998 by Clay Siegall with help from several other experts. Seattle Genetics has made great steps towards delivering reliable ways of combating the effects of cancer and one of the options the company pursued is the ADC Technology, which offers a better solution to cancer treatment.
The ADC Technology is designed to work with only those cells that are affected, deliberately ignoring those that that are healthy. In the traditional method of radiating rays on the cancer cells, specialists could not avoid killing healthy cells. This process of interfering with cells that were not infected further weakened the patient and led to the development of many other problems that would later prove fatal. However, with the ADC Technology, this is no longer something to worry about since the technology allows experts to focus on the cells that are affected and allow patients to heal without experiencing other problems.
About Clay Siegall
Clay Siegall, a highly experience and skilled clinical scientist, is the CEO of Seattle Genetics, a leading company in the cancer research industry. Seattle Genetics, under the leadership of Clay Siegall, has seen a growth in its shares and is now among the best providers of solutions to the cancer menace. Clay Siegall has been choosing professionals to join the team of researchers and his company has facilitated research and the development of new drugs.
After achieving their goal of making better drug pipelines, Seattle Genetics saw its revenues rise in the past five years. Clay Siegall has also helped the company to partner with other leading players in the industry to strengthen the fight against cancer. Some of the companies he invited include Pfizer, GlaxoSmithKline and AbbVie, which have been offering support to the development of new drug pipelines and methods of treating cancer.